A PBPK model to predict disposition of CYP3A-metabolized drugs in pregnant women: Verification and discerning the site of CYP3A induction

CPT: Pharmacometrics and Systems Pharmacology

Volumn 1, Issue 1, 2012, Pages

  Ke, A B ^a,b   Nallani, S C ^b   Zhao, P ^b   Rostami Hodjegan, A ^c,d   Unadkat, J D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d CERTARA UK LIMITED   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; INDINAVIR; MIDAZOLAM; NIFEDIPINE;

AREA UNDER THE CURVE; ARTICLE; DRUG DOSE COMPARISON; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; MATHEMATICAL MODEL; PHARMACOLOGICAL PARAMETERS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PREDICTION; PREGNANT WOMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; SENSITIVITY ANALYSIS; STEADY STATE;

EID: 84872703135     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2012.2     Document Type: Article

References (43)

1. Glover, D.D., Amonkar, M., Rybeck, B.F. & Tracy, T.S. Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population. Am. J. Obstet. Gynecol. 188, 1039-1045 (2003
2. Andrade, S.E. et al. Prescription drug use in pregnancy. Am. J. Obstet. Gynecol. 191, 398-407 (2004
3. Anderson, G.D. & Carr, D.B. Effect of pregnancy on the pharmacokinetics of antihypertensive drugs. Clin. Pharmacokinet. 48, 159-168 (2009
4. Hebert, M.F. et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: A University of Washington specialized center of research study. Clin. Pharmacol. Ther. 84, 248-253 (2008
5. Unadkat, J.D. et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob. Agents Chemother. 51, 783-786 (2007
6. Bryson, Y.J. et al.; PACTG 353 Team. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin. Trials 9, 115-125 (2008
7. Anderson, G.D. Pregnancy-induced changes in pharmacokinetics: A mechanistic-based approach. Clin. Pharmacokinet. 44, 989-1008 (2005
8. Rowland, M., Peck, C. & Tucker, G. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu. Rev. Pharmacol. Toxicol. 51, 45-73 (2011
9. Andrew, M.A., Hebert, M.F. & Vicini, P. Physiologically based pharmacokinetic model of midazolam disposition during pregnancy. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2008, 5454-5457 (2008
10. Jamei, M., Dickinson, G.L. & Rostami-Hodjegan, A. A framework for assessing interindividual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 24, 53-75 (2009
11. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011
12. Abduljalil, K., Furness, P., Johnson, T.N., Rostami-Hodjegan, A., Soltani, H. physiological, anatomical and metabolic changes with gestational age during normal pregnancy: A database for parameters required in physiologically based pharmacokinetic modelling. Clin. Pharmacokinet. 51, 365-396 (2012
13. Lu, G., Abduljalil, K., Jamei, M., Johnson, T.N., Soltani, H. & Rostami-Hodjegan, A. physiologically-based pharmacokinetic (PBPK) models for assessing the kinetics of xenobiotics during pregnancy: Achievements and shortcomings. Curr. Drug Metab. 13, 695-720 (2012
14. Gaohua, L., Abduljalil, K., Jamei, M., Johnson, T.N. & Rostami-Hodjegan, A. A Pregnancy Physiologically-Based Pharmacokinetic (p-PBPK) Model for Disposition of Drugs Metabolized by CYP1A2, CYP3A4 and CYP2D6. Br. J. Clin. Pharmacol. (2012);e-pub ahead of print 22 June 2012.
15. Kirby, B.J. et al. Complex drug interactions of HIV protease inhibitors 2: In vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir. Drug Metab. Dispos. 39, 2329-2337 (2011
16. Rostami-Hodjegan, A., Kroemer, H.K. & Tucker, G.T. In-vivo indices of enzyme activity: The effect of renal impairment on the assessment of CYP2D6 activity. Pharmacogenetics 9, 277-286 (1999
17. Prevost, R.R., Akl, S.A., Whybrew, W.D. & Sibai, B.M. Oral nifedipine pharmacokinetics in pregnancy-induced hypertension. Pharmacotherapy 12, 174-177 (1992
18. Foster, T.S., Hamann, S.R., Richards, V.R., Bryant, P.J., Graves, D.A. & McAllister, R.G. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J. Clin. Pharmacol. 23, 161-170 (1983
19. Yeh, K.C., Stone, J.A., Carides, A.D., Rolan, P., Woolf, E. & Ju, W.D. Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: Study design and model-independent data analysis. J. Pharm. Sci. 88, 568-573 (1999
20. Tracy, T.S., Venkataramanan, R., Glover, D.D. & Caritis, S.N. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am. J. Obstet. Gynecol. 192, 633-639 (2005
21. Tuntland, T., Nosbisch, C. & Unadkat, J.D. Effect of pregnancy, mode of administration and neonatal age on the pharmacokinetics of zalcitabine (2', 3'-dideoxycytidine) in the pigtailed macaque (Macaca nemestrina). J. Antimicrob. Chemother. 40, 687-693 (1997
22. Tuntland, T., Odinecs, A., Nosbisch, C. & Unadkat, J.D. In vivo maternal-fetal-amniotic fluid pharmacokinetics of zidovudine in the pigtailed macaque: Comparison of steady-state and single-dose regimens. J. Pharmacol. Exp. Ther. 285, 54-62 (1998
23. Fahmi, O.A. et al. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: Predictions of compounds as precipitants of interaction. Drug Metab. Dispos. 37, 1658-1666 (2009
24. Zhang, H., Wu, X., Wang, H., Mikheev, A.M., Mao, Q. & Unadkat, J.D. Effect of pregnancy on cytochrome P450 3a and P-glycoprotein expression and activity in the mouse: mechanisms, tissue specificity, and time course. Mol. Pharmacol. 74, 714-723 (2008
25. Jeong, H. Altered drug metabolism during pregnancy: hormonal regulation of drugmetabolizing enzymes. Expert Opin. Drug Metab. Toxicol. 6, 689-699 (2010
26. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Pharmacokinetics in Pregnancy -Study Design, Data Analysis, and Impact on Dosing and Labeling. US FDA webiste [online]: (2004
27. Papageorgiou, I. & Unadkat, J.D. Mechanisms by which hepatic CYP3A enzymes are induced during pregnancy. ISSX, 17th North American Meeting Atlanta, Georgia (2011
28. Obach, R.S., Lombardo, F. & Waters, N.J. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 36, 1385-1405 (2008
29. Gertz, M., Harrison, A., Houston, J.B. & Galetin, A. Prediction of human intestinal firstpass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab. Dispos. 38, 1147-1158 (2010
30. Thummel, K.E. et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59, 491-502 (1996
31. Gorski, J.C., Jones, D.R., Haehner-Daniels, B.D., Hamman, M.A., O'Mara, E.M. Jr & Hall, S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64, 133-143 (1998
32. Reitberg, D.P., Love, S.J., Quercia, G.T. & Zinny, M.A. Effect of food on nifedipine pharmacokinetics. Clin. Pharmacol. Ther. 42, 72-75 (1987
33. Smith, S.R., Kendall, M.J., Lobo, J., Beerahee, A., Jack, D.B. & Wilkins, M.R. Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration. Br. J. Clin. Pharmacol. 23, 311-315 (1987
34. Odou, P. et al. Grapefruit juice-nifedipine interaction: Possible involvement of several mechanisms. J. Clin. Pharm. Ther. 30, 153-158 (2005
35. Balani, S.K. et al. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. Drug Metab. Dispos. 24, 1389-1394 (1996
36. Lin, J.H., Chen, I.W., Vastag, K.J. & Ostovic, D. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23, 730-735 (1995
37. Gertz, M., Houston, J.B. & Galetin, A. Physiologically-based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. Drug Metab Dispos. 39, 1633-1642 (2011
38. Ito, K., Ogihara, K., Kanamitsu, S. & Itoh, T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab. Dispos. 31, 945-954 (2003
39. Kirby, B.J., Collier, A.C., Kharasch, E.D., Whittington, D., Thummel, K.E. & Unadkat, J.D. Complex drug interactions of HIV protease inhibitors 1: Inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab. Dispos. 39, 1070-1078 (2011
40. Lin, J.H. et al. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24, 1111-1120 (1996
41. Product label for CRIXIVAN (indinavir sulfate) oral capsule. .
42. Yang, J., Jamei, M., Yeo, K.R., Tucker, G.T. & Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab. 8, 676-684 (2007
43. Darwich, A.S., Neuhoff, S., Jamei, M. & Rostami-Hodjegan, A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: A simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr. Drug Metab. 11, 716-729 (2010